Merck’s Welireg Gets Orphan Pricing Ahead Of Broader RCC Indications
Drug From $1.1bn Peloton Buy Boosts Renal Cancer Franchise
The company set a $26,400 per month list price for the HIF-2α inhibitor in its first US FDA-approved indication of VHL disease-associated tumors, but the drug is being studied in broader populations.
You may also be interested in...
Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Keeping Track: Merck & Co. In Spotlight With Welireg, Keytruda Approvals; FibroGen/AZ Roxadustat CRL Is No Surprise
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.